Rabeprazole Sodium 20mg + Levosulpiride 75mg
Rabeprazole 20mg (irreversible H⁺/K⁺-ATPase inhibition with CYP2C19-independent activation) + Levosulpiride 75mg (selective peripheral D2/D3 antagonism — prokinetic + anti-emetic). This combination pairs rabeprazole's pharmacokinetic advantages (faster onset, consistent metaboliser-independent acid suppression) with levosulpiride's dual GI-psychiatric D2 activity. See SOUNDRAB™ DSR and PANSWING™ LS for full mechanism details.
GORD with gastroparesis, functional dyspepsia, non-ulcer dyspepsia, diabetic gastroparesis with reflux, and conditions where the psychiatric prokinetic activity of levosulpiride (mild antidepressant/anxiolytic D2 effect at 75mg) provides additional benefit — functional dyspepsia with comorbid anxiety or mild depression. The SOUNDRAB™ brand ensures prescribers associate the rabeprazole advantage with this combination.
Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.
SOUNDRAB LS positions the SOUNDRAB™ brand in the prokinetic-PPI combination category alongside SOUNDRAB™ DSR (domperidone SR version), allowing gastroenterologists who prefer levosulpiride over domperidone (particularly for patients with prominent nausea or mild comorbid anxiety) to maintain brand continuity within the SOUNDRAB™ family.
Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.